Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2011

View Archived Issues

TRPM8 antagonists show potential for treating overactive bladder

Researchers at Roche patent novel GlyT-1 inhibitors

Pentoxifylline improves erectile function following cavernous nerve injury in rats

Sirolimus stabilizes lung function in lymphangioleiomyomatosis

Targeting TNF-alpha inhibits endotoxin-induced airways' neutrophilia in humans

Promising first-in-human data on TLR8 agonist VTX-1463 in allergic rhinitis disclosed

Reduced flares and decreased pain seen with canakinumab in gouty arthritis trials

Positive results reported for phase II AAV2-GAD gene therapy study in Parkinson's disease

Roche presents novel NK3 receptor antagonists for CNS disorders

Vifor designs new hepcidin antagonists for anemia

Novel GlyT-1 inhibitors patented by GSK

GSK describes new orexin receptor antagonists

Tarsa's oral calcitonin meets primary endpoint in pivotal trial

AltheRx acquires solabegron from GSK

FDA approves Zyclara cream for external genital warts

MSD seeks additional indication for Pegintron/rivabirin for compensated cirrhosis due to HCV

GSK withdraws regulatory applications for dutasteride for prostate cancer risk reduction

Nycomed submits MAA to EMA for teduglutide in short bowel syndrome

FDA approves Evolva's IND for EV-077 in influenza

BMS' ipilimumab approved in U.S. for unresectable or metastatic melanoma

Preclinical results on MK-3901 for the treatment of chronic pain presented at ACS meeting

FDA advises NeuroSearch of need for additional data for Huntexil in Huntington's

Genentech's second phase III study of Lucentis in diabetic macular edema meets primary endpoint

Mersana Therapeutics initiates phase Ib extension of XMT-1001 in gastric cancer and NSCLC

FDA requests further survival data for Oxigene's Zybrestat in anaplastic thyroid cancer

Phase I trial to assess MLN-9708 in relapsed/refractory light chain amyloidosis under way

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...